Patents by Inventor Boon Hwa CHOO
Boon Hwa CHOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018221Abstract: The invention relates generally to antigen-binding molecules that specifically bind to Myosin Heavy Chain 9 (MYH9) and uses thereof for the treatment of specific cancers, such as mast cell tumors. In one embodiment, the MYH9 is canine MYH9 and the antigen-binding molecule is an antibody. In another embodiment, the antigen-binding molecule is conjugated to a toxin, for the treatment of canine mast cell tumors.Type: ApplicationFiled: October 26, 2021Publication date: January 18, 2024Applicant: Agency for Science, Technology and ResearchInventors: Wey Jia FONG, Boon Hwa CHOO, Mei Yee Vanessa DING, Chui Ping CHIN
-
Patent number: 11820821Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.Type: GrantFiled: December 22, 2021Date of Patent: November 21, 2023Assignees: SINGAPORE HEALTH SERVICES PTE LTD, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Hau Wan Leung, Andre Boon Hwa Choo, Mei Yee Vanessa Ding, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
-
Patent number: 11697681Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS and a VHCDR3 having the amino acid sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSNDQKNYLA, a VLCDR2 having the amino acid sequence WASIRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT.Type: GrantFiled: April 14, 2020Date of Patent: July 11, 2023Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simeon Cua, Andre Boon Hwa Choo, Heng Liang Tan, Wey Jia Fong, Vanessa Mei Yee Ding, Leonard Wen Yan Leong
-
Publication number: 20220213189Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.Type: ApplicationFiled: December 22, 2021Publication date: July 7, 2022Inventors: Hau Wan Leung, Andre Boon Hwa CHOO, Mei Yee Vanessa DING, Shao Weng Daniel TAN, Narayanan Gopalakrishna IYER
-
Patent number: 11236160Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.Type: GrantFiled: October 10, 2017Date of Patent: February 1, 2022Assignees: SINGAPORE HEALTH SERVICES PTE LTD, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Hau Wan Leung, Andre Boon Hwa Choo, Mei Yee Vanessa Ding, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
-
Patent number: 11142585Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof. In particular, the present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to ERBB2. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.Type: GrantFiled: May 12, 2017Date of Patent: October 12, 2021Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Heng Liang Tan, Andre Boon Hwa Choo
-
Patent number: 11124579Abstract: An antigen-binding protein, or an antigen-binding fragment thereof that binds to a Lewis X type glycan on SLAMF7, comprising (1) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYTFTSYWIH; a VHCDR2 having the amino acid sequence EINPSNGRTNFNEKFKN and a VHCDR3 having the amino acid sequence VDYDEAY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence RSSKSLLHSNGITYLY, a VLCDR2 having the amino acid sequence QMSNLAS, and a VLCDR3 having the amino acid sequence AQNLELWT is provided. Methods of using the antibody for detecting or treating cancer, and a kit comprising the antibody are also provided.Type: GrantFiled: March 29, 2018Date of Patent: September 21, 2021Assignees: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, NATIONAL UNIVERSITY OF SINGAPOREInventors: Chong Kok Teo, Andre Boon Hwa Choo, Wee Joo Chng
-
Publication number: 20200399353Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS and a VHCDR3 having the amino acid sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSNDQKNYLA, a VLCDR2 having the amino acid sequence WASIRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT.Type: ApplicationFiled: April 14, 2020Publication date: December 24, 2020Inventors: Simeon CUA, Andre Boon Hwa CHOO, Heng Liang TAN, Wey Jia FONG, Vanessa Mei Yee DING, Leonard Wen Yan LEONG
-
Publication number: 20200325246Abstract: The present invention relates to antigen-binding proteins, or antigen-binding fragments thereof. In particular, the present invention relates to antigen-binding proteins, or antigen-binding fragments thereof that bind to ERBB2. Compositions comprising a physiologically acceptable carrier and a therapeutically effective amount of the antigen-binding protein, or antigen-binding fragment thereof, use of the antigen-binding protein, or antigen-binding fragment thereof, methods for detecting cancer as well as kits when used in such methods are also provided.Type: ApplicationFiled: May 12, 2017Publication date: October 15, 2020Inventors: Heng Liang TAN, Andre Boon Hwa Choo
-
Patent number: 10654921Abstract: The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence GYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.Type: GrantFiled: July 26, 2017Date of Patent: May 19, 2020Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simeon Cua, Andre Boon Hwa Choo, Heng Liang Tan, Wey Jia Fong, Vanessa Mei Yee Ding, Leonard Wen Yan Leong
-
Publication number: 20200024359Abstract: An antigen-binding protein, or an antigen-binding fragment thereof that binds to a Lewis X type glycan on SLAMF7, comprising (1) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYTFTSYWIH; a VHCDR2 having the amino acid sequence EINPSNGRTNFNEKFKN and a VHCDR3 having the amino acid sequence VDYDEAY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence RSSKSLLHSNGITYLY, a VLCDR2 having the amino acid sequence QMSNLAS, and a VLCDR3 having the amino acid sequence AQNLELWT is provided. Methods of using the antibody for detecting or treating cancer, and a kit comprising the antibody are also provided.Type: ApplicationFiled: March 29, 2018Publication date: January 23, 2020Inventors: Chong Kok Teo, Andre Boon Hwa Choo, Wee Joo Chng
-
Publication number: 20190233514Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.Type: ApplicationFiled: October 10, 2017Publication date: August 1, 2019Inventors: Hau Wan LEUNG, Andre Boon Hwa CHOO, Mei Yee vanessa DING, Shao Weng Daniel Tan, Narayanan Gopalakrishna Iyer
-
Publication number: 20190177405Abstract: The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence GYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.Type: ApplicationFiled: July 26, 2017Publication date: June 13, 2019Inventors: Simeon CUA, Andre Boon Hwa CHOO, Heng Liang TAN, Wey Jia FONG, Vanessa Mei Yee DING, Leonard Wen Yan LEONG
-
Publication number: 20090029461Abstract: The invention relates to an immortalized feeder cell line. The immortalized feeder cell line may be derived from an embryonic fibroblast, which may be a mouse embryonic fibroblast. A culture of an immortalized feeder cell line according to the invention in a suitable culture medium is also provided, as is a composition including an immortalized feeder cell line according to the invention in a suitable carrier or diluent and conditioned medium produced from growth of an immortalized feeder cell line according to the invention. The invention further provides a method of culturing a stem cell including use of a cell line or conditioned medium according to the invention and cells so produced.Type: ApplicationFiled: February 23, 2006Publication date: January 29, 2009Applicant: AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCHInventors: Andre Boon Hwa Choo, Steve Kah Weng Oh